Barbara Tilley to Antiparkinson Agents
This is a "connection" page, showing publications Barbara Tilley has written about Antiparkinson Agents.
Connection Strength
0.758
-
Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology. 2006 Mar 14; 66(5):628-33.
Score: 0.264
-
Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015 Feb 10; 313(6):584-93.
Score: 0.122
-
Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience. Arch Neurol. 2009 Sep; 66(9):1099-104.
Score: 0.083
-
Self-reported adherence versus pill count in Parkinson's disease: the NET-PD experience. Mov Disord. 2007 Apr 30; 22(6):822-7.
Score: 0.071
-
Screening potential therapies: lessons learned from new paradigms used in Parkinson disease. Stroke. 2007 Feb; 38(2 Suppl):800-3.
Score: 0.070
-
Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials. 2005; 2(6):509-18.
Score: 0.061
-
Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial. Trials. 2022 Oct 06; 23(1):855.
Score: 0.052
-
Autonomic and electrocardiographic findings in Parkinson's disease. Auton Neurosci. 2017 07; 205:93-98.
Score: 0.036